Quantitative-imaging in Cardiac Transthyretin Amyloidosis

Recruiting now

Conditions studied: ATTR-CM

In brief

Transthyretin amyloid cardiomyopathy (ATTR-CM), is a heart muscle disease that's stops the heart muscle working properly. With an ageing population, it is increasingly common but untreated, it has a poor prognosis. Several novel expensive treatments have become available, although we do not understand exactly how they work and why some patients respond, and others do not. The challenge is to develop better methods for monitoring the effects of these treatments, maximizing their benefits and cost-effectiveness. In I-CARE we aim to bring a new imaging technique, named 18F-fluoride PET, to the clinic and thereby improve the care of patients with ATTR-CM. Hypotheses: 1. A delayed imaging protocol and state-of-the-art PET motion correction will optimise 18F-fluoride imaging in ATTR-CM and provide a clear threshold in myocardial TBR values for the diagnosis of ATTR-CM. 2. Optimised 18F-fluoride PET will provide a quantitative marker of the ATTR-CM burden that will allow disease progression and treatment response to be tracked. 3. Myocardial 18F-fluoride TBR values will reduce in patients responding to tafamidis treatment and increase in non-responders and patients not receiving therapy

Key facts

Study ID

NCT05776212

Run by

University of Edinburgh

People needed

140

Starts

2021-08-25

Expected to finish

2026-09-30

Last updated by the study team

2026-06-26

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completion of informed consent
• Age > 40 years for patients with ATTR or AL cardiac amyloidosis and age >30 years for patients with HCM
• ATTR cardiac amyloid according to Expert Consensus Recommendations
• AL amyloidosis according to Expert Consensus Recommendations
• Hypertrophic cardiomyopathy according to European Society of Cardiology guidelines

You may not qualify if…

• Inability or unwilling to give informed consent
• Women who are pregnant, breastfeeding or of child-bearing potential (women who have experienced menarche, are pre-menopausal and have not been sterilised) will not be enrolled into the trial.
• Renal dysfunction (eGFR ≤30 mL/min/1.73m2)
• NYHA Class IV heart failure
• Patients with atrial fibrillation and poor rate control.
• Contraindications to MR
• Previous history of contrast allergy of adverse reactions (gadolinium)
• Contraindications to tafamidis therapy

Where it is running

• University Medical Centre Groningen — Groningen, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.